← The record

Glycomacropeptide And Essential Amino Acids

Recommended MetabolicRestrictedNot applicable line

Treatment of phenylketonuria (PKU).

1
Submissions
2016–16
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Nov 2016
    Recommended

    vs Camino Pro Restore®

  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC recommended the listing of PKU Restore® for the treatment of phenylketonuria on a cost-minimisation basis against Camino Pro Restore® at an equivalent cost per gram of protein.PSD · Nov 2016
6.2 The PBAC noted the advice of the Nutritional Products Working Party (NPWP) that supported the decision to list PKU Restore® on the PBS.PSD · Nov 2016

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated. Product assessed on equivalent cost per gram of protein against comparator.

The PBAC recommended the listing of PKU Restore® for the treatment of phenylketonuria on a cost-minimisation basis against Camino Pro Restore® at an equivalent cost per gram of protein. PBAC · 2016
Cost-effectiveness accepted

Decision context

PopulationChildren aged 2 years or older with phenylketonuria requiring nutritional management with glycomacropeptide-based medical foods.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2016 Recommended Camino Pro Restore® RCT · Other

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to PKU in children ≥2 years requiring glycomacropeptide-based medical foods; TGA label covers all foods meeting Standard 2.9.5.